Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.

PHILADELPHIA, March 16, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced that  Babar K. Rao, MD, FAAD, an internationally recognized academic dermatologist and Principal Investigator of the SKNJCT-003 Phase 2 clinical study, will join the Company's leadership team during a business update webcast on March 26, 2026 at 11:30 a.m. Eastern time.

The SKNJCT-003 study represents a randomized, double-blind Phase 2 clinical trial designed to rigorously evaluate the therapeutic contribution of doxorubicin delivered through the SkinJect® microneedle platform in patients with nodular basal cell carcinoma.